Hikma Pharmaceuticals PLC (HIK.L) Company Profile | Reuters.com
Edition:
United States

Profile: Hikma Pharmaceuticals PLC (HIK.L)

HIK.L on London Stock Exchange

2,303.00GBp
5:38am EDT
Change (% chg)

60.00p (+2.67%)
Prev Close
2,243.00p
Open
2,277.00p
Day's High
2,303.00p
Day's Low
2,256.00p
Volume
66,635
Avg. Vol
719,645
52-wk High
2,520.00p
52-wk Low
1,575.00p

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe. The Company's segments include Branded, Injectables, Generics and Others. The Branded business sells branded generics and in-licensed products across the MENA region and other markets. The Injectables business sells specialized generic injectable products across the globe. The Generics business sells non-injectable generic products in the United States. The Branded business has approximately 380 products in over 1,120 dosage forms and strengths. Its products include Amoclan, Blopress, Omnicef, Prograf and Suprax. The Injectables business' products include Argatroban, Fentanyl, Glycopyrrolate, Nicardipine and Phenylephrine.

Company Address

Hikma Pharmaceuticals PLC

13 Hanover Square
LONDON     W1S 1HL
P: +4420.73992760
F: +4420.73992761

Company Web Links